MeiraGTx Holdings plc

Listed Company

MGTXCIK 0001735438NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

$81.39M

Net Income

$-114.20M

Total Assets

$244.43M

Equity

$-5.79M

Shares Out

81.45M

Op. Cash Flow

$-46.40M

Business

MeiraGTx Holdings plc is a vertically integrated, clinical‑stage genetic medicines company developing AAV‑based gene therapies and a proprietary riboswitch gene‑regulation platform. It offers product candidates targeting Parkinson’s disease, radiation‑induced xerostomia, AIPL1‑associated retinal dystrophy and other inherited and degenerative ocular, neurodegenerative and metabolic conditions, together with in‑house GMP viral vector, plasmid DNA production and quality control services. Its key business areas comprise clinical and preclinical therapeutic programs, the riboswitch gene regulation platform, and commercial manufacturing and QC divisions. MeiraGTx advances therapies via clinical trial networks, strategic collaborations and manufacturing supply across North America, the UK, the EU and other international markets.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	81	33	14	—	—
Cost of service revenue - related party	5	24	—	—	—
General and administrative	53	54	47	47	44
Research and development	130	119	104	86	67
Total operating expenses	187	197	151	132	110
Loss from operations	−106	−164	−137	−116	−73
Foreign currency gain (loss)	2	−3	9	−9	6
Interest income	2	4	2	777,000	212,000
Interest expense	−12	−13	−13	−5	−288,000
Gain on sale of nonfinancial assets	—	28	54	—	—
Net loss	−114	−148	−84	−130	−80
Foreign currency translation gain (loss)	6	−2	−7	9	2
Comprehensive loss	−108	−150	−92	−121	−77
Net loss	−114	−148	−84	−130	−80
Basic net loss per ordinary share	−1.42	−2.12	−1.49	−2.87	−1.8
Diluted net loss per ordinary share	−1.42	−2.12	−1.49	−2.87	−1.8
Weighted-average number of ordinary shares outstanding, basic	80	70	56	45	44
Weighted-average number of ordinary shares outstanding, diluted	80	70	56	45	44

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	66	104	130	116	138
Accounts receivable - related party	3	707,000	10	21	—
Contract assets - related party	—	950,000	—	—	—
Inventory	—	385,000	—	—	—
Prepaid expenses	6	7	6	8	8
Tax incentive receivable	15	9	13	8	—
Other current assets	2	2	1	2	2
Total Current Assets	92	124	160	154	183
Property, plant and equipment, net	105	103	116	109	76
Intangible assets, net	578,000	821,000	1	1	2
Restricted cash	2	2	1	—	—
Other assets	1	1	2	1	1
Equity method and other investments	7	7	7	6	—
Right-of-use assets - operating leases, net	13	11	16	20	23
Right-of-use assets - finance leases, net	24	22	24	25	28
TOTAL ASSETS	244	270	327	318	320
Accounts payable	10	24	16	17	15
Accrued expenses	33	27	43	40	28
Lease obligations - operating leases, current	3	4	4	4	3
Lease obligations - finance leases, current	38,000	—	—	—	—
Deferred revenue - related party, current	2	5	3	15	—
Note payable, net, current	25	—	—	—	—
Other current liabilities	50	903,000	1	7	—
Total Current Liabilities	123	61	67	82	68
Deferred revenue - related party	65	58	34	27	—
Lease obligations - operating leases	11	8	13	17	20
Lease obligations - finance leases	109,000	—	—	—	—
Asset retirement obligations	1	3	2	2	2
Note payable, net	50	73	72	71	—
TOTAL LIABILITIES	250	202	189	200	135
COMMITMENTS AND CONTINGENCIES (Note 15)	—	—	—	—	—
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 81,120,931 and 78,397,380 shares issued and outstanding at December 31, 2025 and 2024, respectively	3,000	3,000	2,000	2,000	2,000
Capital in excess of par value	808	774	694	582	529
Accumulated other comprehensive gain (loss)	2	−4	−1	6	−3
Accumulated deficit	−816	−702	−554	−470	−341
Total Shareholders' (Deficit) Equity	−6	68	138	118	185
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY	244	270	327	318	320

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−114	−148	−84	−130	−80
Share-based compensation expense	22	25	28	29	21
Depreciation and amortization	13	13	14	9	8
Change in right-of-use assets	7	4	—	—	—
Gain on termination of lease liabilities	−1	−172,000	—	—	—
Loss on disposal of equipment, furniture and fixtures	355,000	9,000	—	—	56,000
Loss on equity method investment	—	17,000	6,000	—	9,000
Amortization of interest on asset retirement obligations	153,000	209,000	177,000	168,000	—
Amortization of debt discount	1	1	1	444,000	—
Acquired in-process research and development	568,000	—	1	—	—
Accounts receivable - related party	−2	6	10	1	16
Contract assets - related party	986,000	−954,000	—	—	—
Inventory	428,000	−387,000	—	—	—
Prepaid expenses	720,000	−1	3	−329,000	−1
Tax incentive receivable	−6	4	−5	4	—
Other current assets	−365,000	−2	222,000	519,000	2
Other assets, net	−159,000	759,000	−2	−173,000	—
Accounts payable	−12	11	2	4	13
Accrued expenses	4	−14	−382,000	13	8
Change in lease liabilities	−6	−4	—	—	—
Other current liabilities	50	32,000	−1	4	−23,000
Deferred revenue - related party	−731,000	27	−8	−16	−7
Net cash used in operating activities	−46	−104	−105	−73	−11
Purchase of property, plant and equipment	−4	−5	−20	−45	−46
Acquisition of in-process research and development assets	−410,000	—	—	—	—
Proceeds from sale of equipment, furniture and fixtures	129,000	—	—	—	—
Proceeds from sale of nonfinancial assets	—	28	54	—	—
Net cash (used in) provided by investing activities	−4	23	34	−45	−62
Exercise of share options	257,000	—	10,000	231,000	2
Payments of withholdings on shares withheld for income taxes	−3	−2	−2	−3	—
Payments on lease obligations - financing leases	−29,000	—	—	—	−1,000
Proceeds from the issuance of ordinary shares	15	59	92	25	—
Issuance costs in connection with ordinary shares	−39,000	−3	−6	—	—
Net cash provided by financing activities	12	55	84	95	2
Net decrease in cash, cash equivalents and restricted cash	−38	−26	13	−23	−71
Effect of exchange rate changes on cash, cash equivalents and restricted cash	719,000	2	2	674,000	−1
Fixed asset acquisitions included in accounts payable and accrued expenses	1	851,000	3	7	—
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	9	—	—	2	—
Right-of-use assets obtained in exchange for lease liabilities	9	—	—	—	—
Change in estimate of asset retirement obligation	−2	345,000	—	—	—
Reversal of issuance costs	50,000	—	—	—	—
Cash paid for interest	11	12	13	329,000	139,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro